Search research articles
Contact Us
Filters
Showing results (1141-1150 of 1,342) with videos related to
Page
of 135
Sort By:
Fungal Systematics and Evolution
|
March 28, 2024
New and Interesting Fungi. 6
P W Crous, A Akulov, S Balashov, et al.
Blood
|
March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanism
Jiaji G Chen, Xia Liu, Manit Munshi, et al.
Cancer
|
September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study
Jorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Seminars in Hematology
|
May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
Jorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
British Journal of Haematology
|
November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib
Jorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
British Journal of Haematology
|
September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study
Artur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
Leukemia
|
September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Jorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Blood
|
June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
Guang Yang, Jinhua Wang, Li Tan, et al.
The Journal of Pediatrics
|
October 8, 2013
More physically active and leaner adolescents have higher energy intake
Magdalena Cuenca-García, Francisco B Ortega, Jonatan R Ruiz, et al.
Medicine
|
February 23, 2017
Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity
Roser Solans-Laqué, Guadalupe Fraile, Monica Rodriguez-Carballeira, et al.
Page
of 135
Search research articles
Search
Showing results (1141-1150 of 1,342) with videos related to
Sort By:
Page
of 135
Fungal Systematics and Evolution
|
March 28, 2024
New and Interesting Fungi. 6
P W Crous, A Akulov, S Balashov, et al.
Blood
|
March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanism
Jiaji G Chen, Xia Liu, Manit Munshi, et al.
Cancer
|
September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study
Jorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Seminars in Hematology
|
May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
Jorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
British Journal of Haematology
|
November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib
Jorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
British Journal of Haematology
|
September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study
Artur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
Leukemia
|
September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Jorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Blood
|
June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
Guang Yang, Jinhua Wang, Li Tan, et al.
The Journal of Pediatrics
|
October 8, 2013
More physically active and leaner adolescents have higher energy intake
Magdalena Cuenca-García, Francisco B Ortega, Jonatan R Ruiz, et al.
Medicine
|
February 23, 2017
Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity
Roser Solans-Laqué, Guadalupe Fraile, Monica Rodriguez-Carballeira, et al.
Page
of 135